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Abstract
Our group has recently demonstrated that Mycobacterium avium subspecies paratuberculosis (MAP) infection significantly
associates with T1D in Sardinian adult patients. Due to the potential role played by MAP in T1D pathogenesis, it is relevant
to better characterize the prevalence of anti-MAP antibodies (Abs) in the Sardinian population, studying newly diagnosed
T1D children. Therefore, we investigated the seroreactivity against epitopes derived from the ZnT8 autoantigen involved in
children at T1D onset and their homologous sequences of the MAP3865c protein. Moreover, sera from all individuals were
tested for the presence of Abs against: the corresponding ZnT8 C-terminal region, the MAP specific protein MptD, the T1D
autoantigen GAD65 and the T1D unrelated Acetylcholine Receptor. The novel MAP3865c281–287 epitope emerges here as
the major C-terminal epitope recognized. Intriguingly ZnT8186–194 immunodominant peptide was cross-reactive with the
homologous sequences MAP3865c133–141, strengthening the hypothesis that MAP could be an environmental trigger of T1D
through a molecular mimicry mechanism. All eight epitopes were recognized by circulating Abs in T1D children in
comparison to healthy controls, suggesting that these Abs could be biomarkers of T1D. It would be relevant to investigate
larger cohorts of children, followed over time, to elucidate whether Ab titers against these MAP/Znt8 epitopes wane after
diagnosis.
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Type 1 Diabetes (T1D) is a T cell-mediated autoimmune
disease resulting from the destruction of insulin-secreting pancre-
atic b cells. Although it is established that this autoimmune disease
stems from a combination of genetic predisposition and environ-
mental factors, the latter remain elusive [1]. During the period
preceding T1D clinical onset, autoantibodies (aAbs) directed to
islets antigens such as insulin, glutamic acid decarboxylase
(GAD65), insulinoma associated protein-2 and zinc transporter 8
(Znt8) may be detectable for months up to years before disease
onset [2], and progressively wane after diagnosis [3]. Wenzlau
et al. reported that 60–80% of recent-onset T1D harbor antibodies
against Znt8 C terminal domain [4].
Our recent studies suggested that Mycobacterium avium subspecies
paratuberculosis (MAP) infection significantly associates with T1D in
Sardinian population [5]. We reported that anti-MAP and anti-
ZnT8 antibodies (Abs) targeting homologous membrane-spanning
sequences are cross-reactive and capable of eliciting strong
immune responses in T1D adult patients [6], opening the
possibility of a molecular mimicry mechanism precipitating
disease.
Sardinia is one of the regions with the highest incidence of T1D
and multiple sclerosis worldwide, displaying a much higher T1D
prevalence compared to other Mediterranean populations [7].
Several factors, such as genetic isolation, have likely contributed to
the fixing of predisposing alleles. MAP infection is estimated to
affect approximately 60% of Sardinian herds [6], and this
mycobacterium can be found in pasteurized milk products and
may be asymptomatically transmitted to humans [8]. Due to the
potential role played by MAP in T1D pathogenesis, it is relevant to
better characterize the prevalence of anti-MAP Abs in the
Sardinian population. To this end, we investigated the seroreac-
tivity against the previously identified ZnT8/MAP epitopes, in
children at T1D-onset and compared to healthy controls (HCs)
[6]. Moreover, sera from all individuals were tested for the
presence of Abs against 4 newly identified putatively relevant C-
terminal MAP3865c epitopes (MAP3865c246–252, MAP3865c256–
262, MAP3865c261–267 and MAP3865c281–287), the corresponding
ZnT8 C-terminal region, the MAP specific protein MptD, the
T1D autoantigen GAD65 and the T1D unrelated Acetilcoline
Receptor (ACHR).
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Materials and Methods
Subjects
Sardinian new-onset T1D children (n= 29; 15 boys, 14 girls;
mean age 8.664 years; diabetes duration 4.3 days [0–25]);
diagnosed according to the American Diabetes Association criteria
[9]; and Sardinian HCs (n = 30; 14 boys, 21 girls; mean age 863)
were enrolled in Cagliari and Sassari. Patients’ details are provided
in Table S1. Serum samples were processed as previously
described [6].
Ethical Statement
Blood samples were collected after obtaining informed written
consents from the guardians of all subjects. The study protocols
were approved by the ethics committee of the University of Sassari
and Cagliari, Sardinia, Italy.
Peptides
Peptides MAP3865c125–133 (MIAVALAGL) and MAP3865c133–
141 (LAANFVVAL) along with their respective homologous
peptides ZnT8178–186 (MIIVSSCAV), ZnT8186–194 (VAA-
NIVLTV) MAP3865c246–252 (LSPGKDM), MAP3865c256–262
(HLISTGD), MAP3865c261–267 (GDSARVL) and
MAP3865c281–287 (HATVQID) were synthesized at .85% purity
(GL Biochem).
ELISA
Indirect enzyme-linked immunosorbent assay (ELISA) to detect
Abs specific for MAP3865c peptides and MptD protein were
performed as described elsewhere [6]. The cut-off for positivity
was calculated by ROC analysis, setting specificity at 93.3% (i.e.,
Ab+ HCs #6.7%). The percent fraction of Ab+ sera, Area Under
ROC Curve(AUC), and p values after Fisher exact test are
indicated. Results were normalized to a strongly positive control
serum included in all experiments, the reactivity of which was set
at 10.000 arbitrary units (AU)/ml. The statistical significance was
determined using Graphpad Prism 6.0 software.
ElisaRSRTM ZnT8 AbTM (RSR Limited, United Kingdom) kit
for the quantitative determination of autoantibodies (aAbs) to the
ZnT8 C-terminal region (Znt8275–369) in serum was carried out
according to the manufacturer’s instructions.
The concentration of both human GAD65 and human
Acetylcholine Receptor (ACHR) Abs in serum samples from
T1D patients and matched HCs was determined using two
different ELISA kit (MBS, The Netherlands) following the
manufacturer’s instructions.
Results
Abs responses against eight MAP/Znt8 peptides, four falling
into the transmembrane region previously described [6], and four
homologues to the human C-terminal Znt8 immunogenic region,
were analyzed in 29 new-onset T1D children, and 30 age matched
HCs using indirect ELISA. All eight peptides were highly
recognized showing detectable reactivity. Results are summarized
in Figure 1 and Figure 2.
MAP3865c125–133 Abs were detected in 34.5% of T1D subjects
and in 6.7% of HCs, this difference was statistically significant
(Fisher exact test: p=0.0102; AUC=0.72 Fig. 1A).
ZnT8178–186 Ab reactivity was very similar to that of its
homologue MAP3865c125–133 when comparing T1D with HCs
(34.5% and 6.7%, respectively; p=0.0102; AUC=0.75) (Fig. 1B).
MAP3865c133–141 Abs reactivity was the same obtained with the
human homologue ZnT8186–194 when comparing T1D with HCs
(55.2% and in 6.7% respectively; p,0.0001; AUC=0.8 ) (Fig. 1C
and Fig. 1D). MAP3865c246–252 Abs were detected in 27.6% of
T1D subjects and in 3.3% of HCs, this difference being statistically
significant (Fisher exact test: p=0.01; AUC=0.67) (Fig. 2A).
Ab positivity against MAP3865c256–262 was detected in 34.5%
of T1D and only in 3.3% of HCs (p=0.002; AUC=0.63),
showing a statistically significant higher frequency in T1D children
(Fig. 2B).
MAP3865c261–267 Ab reactivity was identified in 31% of T1D
subjects and in 3.3% of HCs, this difference being statistically
significant (Fisher exact test: p=0.005; AUC=0.68) (Fig. 2C).
Ab positivity against the C-terminal MAP3865c281–287 was
detected in 41.4% of T1D and only in 6.7% of HCs (p=0.002;
AUC=0.7), showing a statistically significant higher frequency in
T1D children (Fig. 2D).
The specificity of the MAP/Znt8 peptide based ELISA was
further validated performing the RSR ZnT8 Ab ELISA test.
Commercially available RSR ZnT8 Ab ELISA kit searches and
identifies Abs against C-terminal residues 275–369 inclusive of the
human ZnT8. After carrying out the RSR ZnT8 Ab ELISA 13
positives among 29 T1D (44.8%) were promptly identified,
whereas none of the HCs was positive. The transmembrane
MAP3865c/ZnT8 pairs of homologues peptides and the four C-
terminal MAP3865c peptides were even more sensitive than the
RSR ZnT8 Ab ELISA kit, in fact a range spanning from 8 to 16
(27.6–55.2%) out of 29 T1D patients, were correctly identified.
Noteworthy, the best correlation between the RSR ZnT8 Ab
ELISA kit and the C-terminal MAP3865c peptide is shown in
Figure 3A.
Abs against the MAP-specific protein MptD were searched by
indirect ELISA, highlighting that 14 out of 29 T1D children
(48.3%) vs 1 out of 30 (3.3%) HCs were MptD Abs+ (p,0.0001). A
correlation between Abs recognizing ZnT8RSR and Abs recog-
nizing MptD MAP specific protein is shown in Fig. 3B.
Abs against GAD65, another major T1D autoantigen, and a
totally T1D-unrelated protein ACHR (negative control) were also
searched.
A similar percentage of Ab+ was found against GAD65 and
MAP3865c peptides, whereas no blood sample of diabetic patients
was reported to be positive for ACHR protein. Indeed, 12 out of
29 (41.4%) of T1D children and 2 out of 30 HCs (6.7%) were
found to be positive after carrying out GAD65 ELISA testing.
If we look at T1D subjects, the high frequencies of Abs reacting
against a MAP-specific protein MptD, together with the lack of
Ab+ towards the T1D-unrelated protein ACHR, highlight the
specificity of the MAP3865c/Znt8 based ELISA.
Discussion
The objective of this study was to investigate whether ZnT8/
MAP peptides were recognized in children at T1D-onset. We
asked whether Abs against these epitopes may be markers of T1D
in this pediatric population of Sardinia. This hypothesis is
sustained by two major pieces of evidence.
Firstly, we have recently reported that MAP3865c and ZnT8
homologous sequences were cross-recognized by Abs in Sardinian
T1D adults [6]. Secondly, it has been demonstrated that MAP
infection triggers a specific humoral response in Sardinian T1D
patients, which display high frequencies of Abs reacting against
several mycobacterial proteins [10].
T1D increase is reported worldwide [11], and some evidence
supports the role of infections as a cause of autoimmunity [12].
Our previous findings suggest that MAP infection is associated
with T1D in the Sardinian population [6,10]. Here, we report that
Common Epitopes between Znt8 and MAP3865c
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Abs against MAP3865c125–133, MAP3865c133–141 and MAP3865c
C terminal peptides in conjunction with ZnT8178–186 and
ZnT8186–194 Abs are highly prevalent in Sardinian T1D children,
but marginally so in HCs.
Interestingly, ZnT8-reactive CD8+ T cells are also predomi-
nantly directed against the ZnT8186–194 epitope and are detected
in a majority of T1D patients outside Sardinia [13]. Indeed, Scotto
et al. recently described that 60% of white HLA-A2(+) new T1D
onset children, displayed ZnT8-reactive CD8(+) T cells capable of
recognizing ZnT8186–194. A fraction ranging from 50% to 53% of
the total ZnT8-specific CD8(+) T recognized (VAANIVLTV)
epitope. The same epitope ZnT8185–194, just one amino acid
longer (AVAANIVLTV) was identified by Enee et al. along with
other three Znt8 epitopes [14]. Of value, one of them ZnT8291–300
ILAVDGVLSV was highly conserved showing 50% aminoacid
identity with the corresponding MAP region MAP3865c228–236
LGAVDGVTG. Another one was as well highly conserved
showing 44% aminoacid identity with the homologue MAP
region Znt8228–236 SISVLISAL and MAP3865c167–174 SLGVLIA-
G*(underlined aminoacid residues are conserved, * stands for
gap).
It is known that the number of newly diagnosed cases positive
for ZnT8 Abs is correlated with an older age at diagnosis of T1D
in children and decline following diagnosis [3]. A trend towards an
older age at T1D diagnosis was observed in children positive for
Abs against Znt8178–186 (mean age at diagnosis 11.663.8 vs
7.663.9). Of note, titers against MAP3865c133–141 and ZnT8186–
194 epitopes were similar to the one displayed by MAP3865c125–
133, Znt8178–186 epitopes in T1D and healthy children. Indeed,
Abs against MAP3865c125–133, Znt8178–186 had been previously
found in 65.4% and 68% respectively, T1D adult from Sardinia. It
is to establish if this is due to a loss of tolerance toward these
epitopes in central lymphoid organs as well as in mature
lymphocytes in the periphery. We here provide evidence for an
association between Abs positivity for ZnT8 and MAP homologue
epitopes in Sardinian T1D children. We were also able to
demonstrate the specificity of the recognition, on account of the
high frequencies of Abs reacting against MAP specific MptD
protein, and the total lack of Ab+ towards ACHR (negative
control) protein. The 2 T1D MptD negative patients (but positive
for MAP3865c) may be explained by the lower sensitivity of the
MptD ELISA (due to the poorly conserved conformation of the
protein purified). Likewise, the C-terminal specificity of the MAP
Figure 1. Prevalence of Abs against homologous ZnT8 and MAP3865c transmembrane epitopes in Type 1 Diabetes (T1D), and
healthy controls (HCs) Sardinian children. Sera were tested for their reactivity against plate-coated with MAP3865c125–133(A) and its
homologous ZnT8178–186 (B); and with MAP3865c133–141 (C) and its homologous ZnT8186–194 (D). The dotted line lines indicate the cut-off for positivity
used in each assay, as calculated by ROC analysis. The percent fraction of Ab+ sera is indicated on top of each distribution, while bars indicate the
corresponding median6interquartile range. AUC and p values are given in the top right corner. Figure shows representative experiments out of three
performed.
doi:10.1371/journal.pone.0063371.g001
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peptide based ELISA was confirmed by the RSR ZnT8 Ab ELISA
results. Of note all children Abs+ for MAP3865c133–141 were also
positive for its homolog ZnT8186–194 whereas only 7 out of 10
(70%) of children Abs+ for MAP3865c125–133 were as well positive
for ZnT8178–186. This is a first step in understanding the possible
role played by these epitopes in initiating autoimmunity. It is still
Figure 2. Prevalence of Abs against MAP3865c epitopes falling into the region of homology comprising the polymorphic Znt8
325th residue in 29 Type 1 Diabetes (T1D) and 30 healthy controls (HCs) Sardinian children. Sera were tested for their reactivity against
plate-coated with MAP3865c246–252 (A) MAP3865c256–262 (B) MAP3865c261–267 (C) and MAP3865c281–287 (D) peptides. Data representation is the same
as in Fig. 1.
doi:10.1371/journal.pone.0063371.g002
Figure 3. Correlation between titers of RSR ZnT8 Ab and MAP reactive Abs. Correlation is shown between titers of Abs recognizing (A)
ZnT8RSR Abs and MAP3865c281–287 C-terminal epitope; (B) ZnT8RSR Abs and MptD MAP specific protein. Each circle represents the titer of one T1D
child. The dotted line lines indicate the cut-off for positivity used in each assay, as calculated by ROC analysis.
doi:10.1371/journal.pone.0063371.g003
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early to conclude that these peptides are potential biomarker for
disease prediction in T1D at risk children. Further work needs to
analyze larger cohorts of children followed over time to elucidate
whether Ab titers against these MAP/Znt8 epitopes also decrease
after diagnosis. Moreover, it will be relevant to clarify whether
MAP infection and seroreactivity appears before or after T1D
onset. It would be also interesting to look for the presence of MAP
in intestinal tissues of T1D patients [15]. This would be the first
step to sort out among different interpretations: is MAP an
innocent bystander that merely colonizes the host? Is its presence
due to a secondary infection not involved in T1D etiology? Or is
MAP a primary infectious agent triggering b-cell autoimmunity?
Supporting Information
Table S1 Type 1 diabetes patients. *D: positive pediatric
diabetes patient, n = 29; mean age 8.364.2 years; {Days after
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